Cybin Inc reports its fiscal Q2 results for 2021. Advanced several drug development candidates and received a Schedule I manufacturing license. Cash and equivalents of CAD$75.2 million as of September 30, 2021.

Compass Pathways reports successful results from its Phase IIb clinical trial of COMP360 for the treatment of Treatment Resistant Depression (TRD).

The Drug Enforcement Administration is again greatly increasing legal production quotas for illegal Schedule I drugs like psilocybin, MDMA and DMT.

A bill introduced in the Ohio Senate seeks to expand the state’s medical cannabis qualifying condition list to include arthritis, migraines, autism spectrum disorder, spasticity or chronic muscle spasms, hospice care, opioid use disorder, and any other condition for which a patient could benefit from cannabis use, Cleveland.com reports.

Psilocybin-assisted psychotherapy appears to increase both cognitive and neural flexibility in patients with major depressive disorder, according to new research published in Translational Psychiatry.

Levitte Labs announce an LOI for the acquisition of 3 more pharmacies specializing in addiction.

Michigan Gov. Gretchen Whitmer has signed legislation expanding the number of people eligible for medical cannabis licenses, including those previously barred due to a cannabis-related misdemeanor or felony.

Compass Pathways surprised and disappointed the market with its Phase IIb clinical results. Despite the immediate overall selloff on the news, the outlook for many psychedelic stocks is now BETTER.

Novamind reports that four health insurers are now covering its ketamine treatment for Treatment-Resistant Depression.